{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:02:55Z","timestamp":1780815775742,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,30]]},"DOI":"10.7759\/cureus.26457","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T16:34:35Z","timestamp":1656606875000},"source":"Crossref","is-referenced-by-count":6,"title":["Ketogenic Metabolic Therapy for Glioma"],"prefix":"10.7759","author":[{"given":"Kris A","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D","family":"DiDomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth N","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Azadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekokobe","family":"Fonkem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2278-7","article-title":"Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis","volume":"131","author":"Mistry AM","year":"2017","unstructured":"Mistry AM, Hale AT, Chambless LB, Weaver KD, Thompson RC, Ihrie RA. Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis. J Neurooncol. 2017, 131:125-33. 10.1007\/s11060-016-2278-7","journal-title":"J Neurooncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100034016","article-title":"Long-term glioblastoma multiforme survivors: a population-based study","volume":"25","author":"Scott JN","year":"1998","unstructured":"Scott JN, Rewcastle NB, Brasher PM, et al.. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci. 1998, 25:197-201. 10.1017\/s0317167100034016","journal-title":"Can J Neurol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03027-5","article-title":"Eighty percent survival rate at 15\u00a0years for 1p\/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade","volume":"141","author":"Iwadate Y","year":"2019","unstructured":"Iwadate Y, Matsutani T, Hara A, et al.. Eighty percent survival rate at 15\u00a0years for 1p\/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol. 2019, 141:205-11. 10.1007\/s11060-018-03027-5","journal-title":"J Neurooncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npv016","article-title":"Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis","volume":"3","author":"Dong X","year":"2016","unstructured":"Dong X, Noorbakhsh A, Hirshman BR, et al.. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract. 2016, 3:29-38. 10.1093\/nop\/npv016","journal-title":"Neurooncol Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg O","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927, 8:519-30. 10.1085\/jgp.8.6.519","journal-title":"J Gen Physiol"},{"key":"ref6","article-title":"The Oxygen-Transferring Ferment of Respiration. Nobel Lectures","author":"Warburg O","year":"1931","unstructured":"Warburg O. The Oxygen-Transferring Ferment of Respiration. Nobel Lectures. 1931."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg O","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956, 123:309-14. 10.1126\/science.123.3191.309","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova NN","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016, 23:27-47. 10.1016\/j.cmet.2015.12.006","journal-title":"Cell Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6750","article-title":"Heterogeneity in cancer metabolism: new concepts in an old field","volume":"26","author":"Gentric G","year":"2017","unstructured":"Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in cancer metabolism: new concepts in an old field. Antioxid Redox Signal. 2017, 26:462-85. 10.1089\/ars.2016.6750","journal-title":"Antioxid Redox Signal"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-74. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.08.002","article-title":"Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism","volume":"2","author":"Allen BG","year":"2014","unstructured":"Allen BG, Bhatia SK, Anderson CM, et al.. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014, 2:963-70. 10.1016\/j.redox.2014.08.002","journal-title":"Redox Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.06.026","article-title":"Ketogenic diet in the treatment of cancer - where do we stand?","volume":"33","author":"Weber DD","year":"2020","unstructured":"Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer - where do we stand?. Mol Metab. 2020, 33:102-21. 10.1016\/j.molmet.2019.06.026","journal-title":"Mol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.02.016","article-title":"Role of ketogenic metabolic therapy in malignant glioma: a systematic review","volume":"112","author":"Winter SF","year":"2017","unstructured":"Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. Crit Rev Oncol Hematol. 2017, 112:41-58. 10.1016\/j.critrevonc.2017.02.016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12591","article-title":"Ketogenic diets: from cancer to mitochondrial diseases and beyond","volume":"46","author":"Branco AF","year":"2016","unstructured":"Branco AF, Ferreira A, Sim\u00f5es RF, et al.. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest. 2016, 46:285-98. 10.1111\/eci.12591","journal-title":"Eur J Clin Invest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-5563-y","article-title":"Transcriptional profiling of PPAR\u03b1-\/- and CREB3L3-\/- livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPAR\u03b1","volume":"20","author":"Ruppert PM","year":"2019","unstructured":"Ruppert PM, Park JG, Xu X, Hur KY, Lee AH, Kersten S. Transcriptional profiling of PPAR\u03b1-\/- and CREB3L3-\/- livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPAR\u03b1. BMC Genomics. 2019, 20:199. 10.1186\/s12864-019-5563-y","journal-title":"BMC Genomics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00390","article-title":"Exploring the feasibility and effects of a ketogenic diet in patients with CNS malignancies: a retrospective case series","volume":"14","author":"Panhans CM","year":"2020","unstructured":"Panhans CM, Gresham G, Amaral LJ, Hu J. Exploring the feasibility and effects of a ketogenic diet in patients with CNS malignancies: a retrospective case series. Front Neurosci. 2020, 14:390. 10.3389\/fnins.2020.00390","journal-title":"Front Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-8-54","article-title":"Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial","volume":"8","author":"Schmidt M","year":"2011","unstructured":"Schmidt M, Pfetzer N, Schwab M, Strauss I, K\u00e4mmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011, 8:54. 10.1186\/1743-7075-8-54","journal-title":"Nutr Metab (Lond)"},{"key":"ref18","article-title":"Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer","author":"Seyfried TN","year":"2012","unstructured":"Seyfried TN. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons, Inc, Hoboken, NJ; 2012."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036197","article-title":"The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma","volume":"7","author":"Abdelwahab MG","year":"2012","unstructured":"Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, Scheck AC. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012, 7:e36197. 10.1371\/journal.pone.0036197","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz167.033","article-title":"The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemotherapy and radiotherapy","volume":"21","author":"Zeng Q","year":"2019","unstructured":"Zeng Q, Stylianou T, Preston J, et al.. The ketogenic diet alters the epigenetic landscape of GBM to potentiate the effects of chemotherapy and radiotherapy. Neuro Oncol. 2019, 21:iv8. 10.1093\/neuonc\/noz167.033","journal-title":"Neuro Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2016.00122","article-title":"Tumor metabolism, the ketogenic diet and \u03b2-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy","volume":"9","author":"Woolf EC","year":"2016","unstructured":"Woolf EC, Syed N, Scheck AC. Tumor metabolism, the ketogenic diet and \u03b2-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Front Mol Neurosci. 2016, 9:122. 10.3389\/fnmol.2016.00122","journal-title":"Front Mol Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm YH","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, et al.. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015, 21:263-9. 10.1038\/nm.3804","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-1337-2","article-title":"Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes","volume":"37","author":"Klement RJ","year":"2020","unstructured":"Klement RJ, Brehm N, Sweeney RA. Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol. 2020, 37:14. 10.1007\/s12032-020-1337-2","journal-title":"Med Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4889","article-title":"Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization","volume":"26","author":"Woodhouse C","year":"2019","unstructured":"Woodhouse C, Ward T, Gaskill-Shipley M, Chaudhary R. Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization. Curr Oncol. 2019, 26:e433-8. 10.3747\/co.26.4889","journal-title":"Curr Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.725","article-title":"QOLP-04. The ketogenic diet plus standard care for recently diagnosed glioblastoma: a phase 1 safety and feasibility trial","volume":"23","author":"Hu J","year":"2021","unstructured":"Hu J, Amaral LJ, Gresham G, et al.. QOLP-04. The ketogenic diet plus standard care for recently diagnosed glioblastoma: a phase 1 safety and feasibility trial. Neuro Oncol. 2021, 23:vi183. 10.1093\/neuonc\/noab196.725","journal-title":"Neuro Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp R","year":"2007","unstructured":"Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007, 25:4127-36. 10.1200\/JCO.2007.11.8554","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager T","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017, 18:10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6032","article-title":"The FOXM1\/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma","volume":"38","author":"Ma Q","year":"2017","unstructured":"Ma Q, Liu Y, Shang L, Yu J, Qu Q. The FOXM1\/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma. Oncol Rep. 2017, 38:3367-75. 10.3892\/or.2017.6032","journal-title":"Oncol Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01840.x","article-title":"Peroxisome proliferator-activated receptor alpha and the ketogenic diet","volume":"49 Suppl 8","author":"Cullingford T","year":"2008","unstructured":"Cullingford T. Peroxisome proliferator-activated receptor alpha and the ketogenic diet. Epilepsia. 2008, 49 Suppl 8:70-2. 10.1111\/j.1528-1167.2008.01840.x","journal-title":"Epilepsia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00459","article-title":"Alzheimer disease: crosstalk between the canonical Wnt\/beta-catenin pathway and PPARs alpha and gamma","volume":"10","author":"Vall\u00e9e A","year":"2016","unstructured":"Vall\u00e9e A, Lecarpentier Y. Alzheimer disease: crosstalk between the canonical Wnt\/beta-catenin pathway and PPARs alpha and gamma. Front Neurosci. 2016, 10:459. 10.3389\/fnins.2016.00459","journal-title":"Front Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/biom10040655","article-title":"Diseases caused by mutations in mitochondrial carrier genes SLC25: a review","volume":"10","author":"Palmieri F","year":"2020","unstructured":"Palmieri F, Scarcia P, Monn\u00e9 M. Diseases caused by mutations in mitochondrial carrier genes SLC25: a review. Biomolecules. 2020, 10:655. 10.3390\/biom10040655","journal-title":"Biomolecules"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74049-ketogenic-metabolic-therapy-for-glioma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:59Z","timestamp":1707508019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74049-ketogenic-metabolic-therapy-for-glioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.26457","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}